EU approved 114 medicines in 2024
The European Medicines Agency has approved more than 100 new medicines for the first time in fifteen years. Of the 114 medicines given the green light in 2024,… read more.
The European Medicines Agency has approved more than 100 new medicines for the first time in fifteen years. Of the 114 medicines given the green light in 2024,… read more.
Eli Lilly and Company announced the FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound… read more.
Many infants in Sweden are given milk cereal drinks, ready-to-mix liquid drink complements to breast milk, after six months of age. New research in Acta Paediatrica found evidence… read more.
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a… read more.
A new study by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with researchers at Harvard T.H. Chan… read more.
Aligos Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from… read more.
New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use…. read more.
Vitamin D supplements may lower blood pressure in older people with obesity and taking more than the Institutes of Medicine’s (IOM) recommended daily dose does not provide additional… read more.
Researchers report that the number of people in the U.S. who died from ischemic heart disease related to obesity increased by approximately 180% from 1999 to 2020. The… read more.
Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), announced multiple resmetirom data presentations at the upcoming American Association… read more.
A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread… read more.
Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.